Haematopoietic stem cell transplantation (HSCT)
Evidence-based neurology checklist on haematopoietic stem cell transplantation (hsct): Benefits HSCT resets the immune system About 70-80% of recipients are stabilised for 3-5 years The 10-year remission is about 70% It improves the quality of life It also improves functional scores It may be more…
Benefits
- HSCT resets the immune system
- About 70-80% of recipients are stabilised for 3-5 years
- The 10-year remission is about 70%
- It improves the quality of life
- It also improves functional scores
- It may be more effective than other immunosuppressive treatments
Indications
Pre-procedure treatments
HSC harvesting
Conditioning chemotherapy options
Infection-related side effects
Other side effects
Outcome
Predictors of good outcome
References
- Rogojan C, Frederiksen JL. Hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurol Scand 2009; 120:371-382.
- Burman J, Iacobaeus E, Svenningsson A, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. JNNP 2014; 85:1116-1121.
- Nash RA, Hutton GJ, Racke MK, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS)A 3-year interim report. JAMA Neurol 2015; 72:159-169.
- Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nat Rev Neurol 2017; 13:391-405.
- Boffa G, Massacesi L, Inglese M, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology 2021 (Online ahead of print).
- And 8 more. Subscribe to see the full list
